Jean-Marc Limacher, chairman of Odimma Therapeutics and Jessica Matta, CEO of Odimma Thrapeutics had the opportunity to present Odimma’s personalized Immunotherapy platform at the 5th Neoantigen Summit Europe in Amsterdam, 27th and 28th April, an event dedicated to identification, prediction and validation of neoantigens to help the improvement of innovative personnalized medicine in oncology.
To follow our news, you can also connect to our Linkedin page:
www.linkedin.com/company/odimma/